# A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

> **NCT06742190** · PHASE3 · RECRUITING · sponsor: **argenx** · enrollment: 115 (estimated)

## Conditions studied

- Multifocal Motor Neuropathy (MMN)
- MMN

## Interventions

- **BIOLOGICAL:** Empasiprubart
- **BIOLOGICAL:** IVIG (Intravenous Immunoglobulin)
- **OTHER:** Empasiprubart-placebo
- **OTHER:** IVIg-placebo

## Key facts

- **NCT ID:** NCT06742190
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2026-09
- **Final completion:** 2029-12
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742190, "A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT06742190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*